Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 545-553

  Foroutan, Naghmeh ^a   Rasekh, Hamid R ^a   Salamzadeh, Jamshid ^a   Jamshidi, Hamid R ^a   Nafar, Mohsen ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Budget impact; Health insurance; mTOR inhibitors; Out of pocket; Renal transplantation

Indexed keywords

AMLODIPINE; ATORVASTATIN; CITOGAN; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BUDGET; CEREBROVASCULAR ACCIDENT; COST CONTROL; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; GRAFT FAILURE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL COST; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IRAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; PHARMACY; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL GRAFT DYSFUNCTION; RENAL REPLACEMENT THERAPY; SENSITIVITY ANALYSIS; SEPSIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 84885966258     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S51446     Document Type: Article

References (20)

1. Han F, Wu J, Huang H, et al. Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study. Exp Clin Transplant. 2011;9(1):42-49.
2. Kahan B. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc. 1997;29(1-2):48-50.
3. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7): 1036-1042.
4. Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant. 2007;22(Suppl 8):viii61-viii65.
5. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81(9):1234-1248.
6. Büchler M, Caillard S, Barbier S, et al; SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant. 2007;7(11):2522-2531.
7. Nafar M, Alipour B, Ahmadpoor P, et al. Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up. Iran J Kidney Dis. 2012;6(4):300-306.
8. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health. 2007;10(5):336-347.
9. Mahdavi-Mazdeh M, Rouchi AH, Norouzi S, Aghighi M, Rajolani H, Ahrabi S. Renal replacement therapy in Iran. J Urol. 2007;4(2): 66-70.
10. Mehrdad R. Health system in Iran. JMAJ. 2009;52(1):69-73.
11. Hajizadeh M, Nghiem HS. Out-of-pocket expenditures for hospital care in Iran: who is at risk of incurring catastrophic payments? Int J Health Care Finance Econ. 2011;11(4):267-285.
12. MacDonald AS; RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271-280.
13. Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int. 2010;78(11):1068-1074.
14. Einollahi B. Kidney Transplantation in Iran. Iran J Med Sci. 2010; 35(1):1-8.
15. Khosroshahi HT. Short history about renal transplantation program in Iran and the world: Special focus on world kidney day. J Nephropathology. 2012;1(1):5-10.
16. Nuijten MJ, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis. Eur J Health Econ. 2011;12(3):231-241.
17. Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health. 2004;7(1):1-10.
18. Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics. 2008;26(6):477-495.
19. Flechner SM. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant Proc. 2008;40(Suppl 10):S25-S28.
20. McEwan P, Baboolal K, Conway P, Currie CJ. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clin Ther. 2005;27(11):1834-1846.